Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 · New England Journal of Medicine · 5,683 citations
https://doi.org/10.1056/nejmoa040720
I
Ian F. Tannock
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
616
Papers
62.0K
Citations
111
h-index
365
i10-index
Ian F. Tannock is an academic researcher from Ontario Institute for Cancer Research. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Statistical Methods in Clinical Trials & Health Systems, Economic Evaluations, Quality of Life. The author has an h-index of 111, co-authored 524 publications.
ORCID: 0000-0002-2636-7041Papers by this author
worksPrognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 · JNCI Journal of the National Cancer Institute · 3,120 citations
https://doi.org/10.1093/jnci/dju124
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
2014 · The Lancet · 1,745 citations
https://doi.org/10.1016/s0140-6736(13)62416-2
Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 · Cancer Epidemiology Biomarkers & Prevention · 698 citations
https://doi.org/10.1158/1055-9965.epi-14-0146
The Lancet Commission on prostate cancer: planning for the surge in cases
2024 · The Lancet · 517 citations
https://doi.org/10.1016/s0140-6736(24)00651-2
Bone metastases: pathophysiology and management policy.
1991 · Journal of Clinical Oncology · 483 citations
https://doi.org/10.1200/jco.1991.9.3.509
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat